z-logo
open-access-imgOpen Access
A novel hedgehog inhibitor iG2 suppresses tumorigenesis by impairing self‐renewal in human bladder cancer
Author(s) -
Zhu Lihong,
Ni Chen,
Dong Baijun,
Zhang Yong,
Shi Yuefeng,
Niu Haitao,
Li Chong
Publication year - 2016
Publication title -
cancer medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.403
H-Index - 53
ISSN - 2045-7634
DOI - 10.1002/cam4.802
Subject(s) - bladder cancer , cancer research , hedgehog , cancer , hedgehog signaling pathway , carcinogenesis , apoptosis , cancer cell , cancer stem cell , medicine , stroma , biology , microbiology and biotechnology , signal transduction , immunohistochemistry , biochemistry
Tumor recurrence is still a major challenge for clinical treatment of bladder cancer. Cumulative evidences indicate cancer stem cells ( CSC s) contribute to drug resistance and leave a putative source for disease relapse. Identifying novel agents targeting CSC s may represent a new paradigm in the therapy of bladder cancer. Here, we separated a novel hedgehog (Hh) inhibitor, iG 2, from s treptomyces roseofulvus , which dramatically blocked the activation of Gli2 in bladder cancer cells. The iG 2 strongly repressed the growth of cancer cells rather than the peri‐tumor stroma cells. Attenuated proliferation and enhanced apoptosis of tumor cells were observed upon iG 2 stimulation. Furthermore, iG 2 reduced the self‐renewal ability of bladder CSC s as well as the tumor formation. Collectively, iG 2 is potentially used as a novel therapeutic agent for bladder cancer by targeting self‐renewal through inhibiting Hh pathway.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here